ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to with your ASCO member or guest account, and visit the subscription center available under your account profile.

Showing results for Tobacco

August 18, 2017

On August 8, the FDA announced a new public health education campaign aimed at discouraging the use of e-cigarettes and electronic nicotine delivery systems (ENDS) by children. The program will include messaging towards teens about the dangers of these products and a full-scale campaign will be launched in 2018. This marks the first time the FDA will be utilizing public health education to specifically target youth use of e-cigarettes.

August 3, 2017

On July 28, the Food and Drug Administration (FDA) announced a new strategy to address tobacco-related disease and death.  The agency seeks to develop a plan to reduce the nicotine levels in combustible cigarettes to non-addictive levels.  However, as part of the strategy, the FDA also announced it will delay the regulation of e-cigarettes for several years. This regulation was part of the implementation of the Deeming Rule 2021/2022, which was issued last year.

July 25, 2017

Last week, the Maine legislature passed LD 1170, a bill increasing the legal age to purchase tobacco products to age 21. This bill would make Maine only the third state behind Hawaii and California to pass Tobacco 21 legislation.  The vote in the Maine Senate was an overwhelming 31 to 4 in the House was 113 to 34. The bill will take effect in July 2018 and will now go to Governor LePage for signature.

June 16, 2017

A study published in the U.S. Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report on June 15, found a significant drop in the number of teenagers in Oregon using tobacco products from 2015 to 2016.

March 22, 2017

On March 21, Lancet Public Health published a study on the 2003 global tobacco control treaty’s impact on the adoption of tobacco reduction measures around the world, which has led to a 2.5% reduction in global smoking rates. The treaty obligates the 180 countries committed to it to implement strong evidence-based policies. While the US did sign on in 2004, it has never ratified this treaty.

March 20, 2017

On March 15, the Campaign for Tobacco-Free Kids, American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, and American Lung Association issued a new report titled “The Flavor Trap: How Tobacco Companies Are Luring Kids with Candy-Flavored E-Cigarettes and Cigars.”

March 3, 2017

ASCO is tracking legislation that would increase the legal age for the purchase of tobacco products to 21, known as “Tobacco 21,” in multiple states. ASCO worked closely with the Florida Society of Clinical Oncology to submit a joint letter of support on Florida bill 1093. ASCO also sent a support letter for West Virginia bill House bill 2331 and Senate bill 37 and Texas House bill 628 and 1908 and Senate bill 183 and 910.

February 14, 2017

Last week, ASCO submitted joint comment letters with the State Affiliates in Connecticut and Washington in support of legislation that would increase the legal age for the purchase of tobacco products to 21. ASCO is committed to policies that will contribute to reducing prevalence of tobacco use to ultimately prevent the occurrence of cancer and other smoking-caused diseases.  

January 12, 2017

The World Health Organization and the National Cancer Institute released a report on January 10, that finds smoking and its side effects cost the world's economies more than $1 trillion and kill about 6 million people each year. The report also noted that this number is expected to rise by more than a third by 2030. ASCO issued the following statement from President Daniel F. Hayes, MD, FASCO, FACP.